Blog Profile / Pharmalot


URL :http://blogs.wsj.com/pharmalot/
Filed Under:Medical / Pharmaceutical
Posts on Regator:5567
Posts / Week:16.7
Archived Since:November 10, 2008

Blog Post Archive

White House Plan for Limiting Antibiotic Resistance is Criticized

The White House has released a detailed blueprint for combating the growing problem of antibiotic resistance, but consumer advocates say the plan lacks specifics for reducing usage in food-producing animals, which contributes significantly to the problem.

The WHO Suggests Europeans Cooperate to Lower Drug Prices

In a new report, the World Health Organization is urging European countries to share information about the cost-effectiveness of drugs, and also consider off-label use of medicines, as a way to combat budgetary pressures from rising drug prices.

More States Pass ‘Right to Try’ Laws, But Will These Make a Difference?

More states are passing 'right to try' laws to widen access to experimental medicines for people facing life-threatening illnesses, but experts say the laws do not accomplish the goal, while advocates say the laws may spur Congress to act.

Pharmalot.. Pharmalittle.. As the Weekend Nears: We’re Catching up on Novo, Oxycontin and Lots More!!

And so, yet another working week will soon draw to a close. Not a moment too soon, yes? After all, it has been a rather busy week. Now, though, we get to dream about weekend plans. Once again, the agenda is fairly modest. We expect to catch up on some reading, take a nap or three and possibly check in on the Pharmalot ancestors. Show More Summary

FDA is Sued by Otsuka for ‘Unlawfully’ Widening the Market for Ability

Otsuka Pharmaceuticals flied a lawsuit claming the FDA illegally widened the market for its best-selling Abilify drug, opening the door to generic competition sooner than the drug maker expected.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Gilead, Merck and Much More!!

Hello, everyone, and how are you today? We are feeling bright and shiny this morning, despite the tufts of gloomy fog encircling the Pharmalot campus. After all, every brand new should be unwrapped like a precious gift, as the Morning Mayor used to say. Show More Summary

San Francisco may be First Major U.S. City With a Drug-Take Back Program

San Francisco may become the first major U.S. city to require drug makers to fund and administer a citywide take-back program in which consumers can bring unused and unexpired medicines to drop-off destinations for disposal

FDA Scolds Another Indian Drug Maker for Quality Control Problems

The FDA has scolded yet another Indian drug maker - this time, Aarti - for violating manufacturing practices and, as a result, banned shipments of its medicines from the U.S.

Waiting for Godot? FDA Defends Time Needed To Finalize a Draft Guidance

The FDA defended the time it takes to finalize draft guidances for policies and procedures.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Merck, Novartis and Lots More!!

Rise and shine, everyone, the middle of the week is here. You made it this far, so why not forge ahead, yes? As always, we are doing our best with the help of some cups of stimulation - we are quaffing Hazelnut this morning - and invite you to join us. Show More Summary

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching Up On Celgene, Sanofi and Lots More!!

Rise and shine. Another busy day is on the way. A bright, warm sun is enveloping the Pharmalot campus this morning, as we prepare for the latest attempt at tackling our ever-growing to-do list. No doubt, you can relate. So please join us as we hoist another cup of stimulation in hopes of getting a few things done. Show More Summary

AstraZeneca to Disclose Trial Data, but how Independent is its Review Panel?

AstraZeneca becomes the latest drug maker to agree to disclose clinical trial data.

Compound Pharmacists Trade Group Discourages Supplying Execution Meds

The leading trade group for compound pharmacists is now discouraging its members from preparing or dispensing drugs for executions.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Biogen, Daiichi and Lots More!!

Good morning, everyone, and how are you today? A shiny sun is slowly warming the Pharmalot campus, where the shortest of short people has left for the local schoolhouse, the official mascots are happily snoozing and we are brewing another cup of needed stimulation. Show More Summary

Amgen Loses Bid to Block a Biosimilar Version of its Best-Selling Drug

A federal judge denied a bid by Amgen to block Novartis from selling a low-cost copy of a its Neupogen drug that is used to fend off infections during chemotherapy. For now, the decision clears the way for biosimilar developers to more quickly market their medicines following approval by the FDA.

Gilead is Criticized for Restrictions on Generic Hepatitis C Drug Deal

Doctors Without Borders is harshly criticizing Gilead Sciences over an agreement in which several generic companies will sell lower-cost versions of Gilead’s Sovaldi and Harvoni medicines in 91 developing countries.

Pharmalot.. Pharmalittle: As the Weekend Nears, We’re Tracking Glaxo, AstraZeneca and More!!

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you may recall, our treasured signal for daydreaming about weekend plans. As usual, our agenda is rather modest, but we are not complaining. Show More Summary

New Cholesterol Meds May Lower Heart Risks, but Will They Break the Bank?

Will the new type of cholesterol drugs known as PCSK9 inhibitors break the bank?

Copyright © 2015 Regator, LLC